Results 171 to 180 of about 5,026 (198)

Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis

Clinical Neurology and Neurosurgery
Myasthenia gravis (MG) is a chronic, complex autoimmune disorder characterized by the production of autoantibodies that destroy neuromuscular junctions. Blocking the neonatal Fc receptors (FcRn) enhances IgG catabolism, offering a novel therapeutic approach.PubMed, Embase, and the Cochrane Library were searched up to February 2025, for RCTs evaluating ...
Muzamil Akhtar, Mehmood Akhtar, Hanzala Ahmed Farooqi, Ayesha Maryam, Anam Muzammil, Ummara Hanif, Zoya Athar, Syed Muhammad Hassan, Zarak Khan   +8 more
openaire   +2 more sources

Comparative efficacy and safety of FcRn inhibitors versus placebo in adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials

Blood
Abstract Background: Immune thrombocytopenia (ITP) in adults is an autoimmune condition characterized by low platelet counts and an increased risk of bleeding due to accelerated platelet destruction and impaired production.
Akhil Deepak Vatvani, Rama Nada, Timotius Ivan Hariyanto, Nehad Shabarek   +3 more
openaire   +1 more source

FcRn inhibitors in the context of myasthenia gravis

Expert Opinion on Emerging Drugs
Deepak, Menon, Vinaya, Bhandari
openaire   +2 more sources

Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review

International Journal of Molecular Sciences, 2022
Yanis Ramdani, Hervé Watier
exaly  

Applications of FcRn Inhibitors to Antibody-Based Radiopharmaceuticals

Nuclear Medicine and Biology
Tullio Esposito, Kali Jones, Teja Kalidindi, Naga Vara Kishore Pillarsetty   +3 more
openaire   +1 more source

POS1130 DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME

Annals of the Rheumatic Diseases, 2023
J. Hubbard, K. Campbell, K. Sivils, R. Hoffman, K.H. Lo, J.H. Leu, S. Bowman, S. Liva, Q. Zuraw, A.M. Stevens, L. Ling, K. Karcher, S. Ramchandren, H. Sun, R.H. Scofield, R. Seror, D.J. Wallace   +16 more
openaire   +1 more source

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

Proceedings of the National Academy of Sciences of the United States of America, 2015
Hubert Kettenberger, Gerhard Winter, Thomas Emrich   +2 more
exaly  

EE219 Cost per Responder for FcRn Inhibitors for Generalized Myasthenia Gravis

Value in Health
A Betts, A Ting, J Montilva
openaire   +1 more source

Targeting FcRn to Generate Antibody-Based Therapeutics

Trends in Pharmacological Sciences, 2018
E Sally Ward, Raimund J Ober
exaly  

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Science Translational Medicine, 2017
Rocio Lledó-García, Graham Price, Ian White   +2 more
exaly